Anumana named in Fierce Medtech's Fierce 15 for 2022

See Article

Unlocking the language of the heart

Leveraging cutting-edge AI, industry-leading translational science and deep electrophysiological data to transform cardiac care

divider

Anumana™ is an AI-driven health technology company from nference, building and commercializing AI solutions to improve patient care throughout the cardiac care continuum.

Our Impact

The Impact of AI Algorithms in Cardiology

Listen to Dr. Paul Friedman, a Professor of Medicine and Chair of the Department of Cardiovascular Medicine at Mayo Clinic and Anumana advisor, discuss the potential of AI algorithms in advancing early diagnosis and intervention in cardiology.

Diagnostic Electrocardiography

Diagnostic Electrocardiography

Serious cardiovascular diseases affect millions of people worldwide, often going undiagnosed until symptoms advance and patients deteriorate, at times resulting in life-threatening events. Anumana’s AI solutions enable earlier diagnosis of these otherwise hidden diseases, empowering clinicians to intervene with treatments earlier and improve outcomes.

Interventional Electrophysiology

Interventional Electrophysiology

Today, the power of AI is just beginning to be leveraged in EP clinical decision support and can provide immense value during EP procedures.​ Anumana’s algorithms and software have the potential to improve procedure accuracy, reduce procedure times, improve medication management, and improve patient safety and outcomes. 

divider

Why Us

Rich, Proprietary Data 

Anumana has one of the world’s largest electrophysiological data and longitudinal patient history and outcomes in the world. This harmonized, cleaned, and validated dataset was developed from multi-year data partnerships with several health systems from Anumana’s parent company, nference. This real-world evidence generation platform, nSights, is inclusive of 11M patients spanning 20+ years and transforms unstructured data (i.e. clinical notes, echocardiogram reports) and semi-structured (i.e. lab tests, medications, appointments, etc) into labeled data format at scale. This extensive data platform is the basis upon which Anumana’s research is conducted.

Cutting-Edge AI Algorithms

Anumana develops state-of-the-art ECG-AI and EGM-AI algorithms which are rooted in science and backed by a growing body of data. The growing pipeline of ECG-AI algorithms have been validated by over 75 peer-reviewed publications, including The Lancet and Nature.

Innovative Software and Integrations
Innovative Software and Integrations

Anumana builds and commercializes clinician-facing software and solutions to democratize insights from its cardiology-AI. Anumana’s software solutions seamlessly integrate with EMRs and other point-of-care technology used within the clinician’s workflow.

The Tech Tribune
Fierce Biotech
Bostinno
MedCity News
Pulmonary Hypertension News
DAIC
Modern Healthcare
Becker's Hospital Review
Medical Press
Mass Device

Diagnostic Algorithm Pipeline

Innovative diagnostic tools for detecting rare and hidden disease, based on the world’s largest labeled patient dataset, built to be integrated into existing physician workflows and currently pursuing FDA approval.

Program
Development
Pre-Submission
Validation
Submission
Market Authorization
Low Ejection Fraction
Novartis

Granted FDA Breakthrough Device Designation

Phase: Validation

Pulmonary Hypertension

Granted FDA Breakthrough Device Designation

Phase: Pre-Submission

Hyperkalemia

Granted FDA Breakthrough Device Designation

Phase: Development

Cardiac Amyloidosis

Phase: Pre-Submission

Atrial Fibrillation in Normal Sinus Rhythm

Phase: Pre-Submission

Hypertrophic Cardiomyopathy

Phase: Development

Myocarditis

Phase: Development

Aortic Stenosis

Phase: Development

Early Stage Development Programs

Phase: Development

Interventional EP Product Pipeline

Anumana also has a rich pipeline of AI / ML driven products for use in the interventional electrophysiology (EP) setting.

Program
Development
Pre-Submission
Validation
Submission
Authorization
Hardware Agnostic AI / ML based EAM Software

Phase: Submission

EP Case Review Software

FDA Clearance Not Required

Phase: Validation

Signal Identification Software

Phase: Validation

Early Stage Development Programs

Phase: Development

divider

In the Media

Quotes

At Mayo Clinic, AI engineers face an ‘acid test’: Will their algorithms help...

In just the past three years, the team has published more than two dozen studies on AI in cardiology, and it is now field-testing an algorithm to detect a weak heart pump in dozens of primary care clinics.

Stat

Dec. 18th, 2019

Download Our One-Pager

Featuring key corporate highlights and an overview of Anumana's technology